Back to speakers

Mitchell SHIFFMAN

Director Liver Institute of Virginia

USA

City: Richmond

Institution: Liver Institute of Virginia

Contact: Mitchell_Shiffman@bshsi.org


Biography of Mitchell SHIFFMAN

Dr Mitchell L Shiffman is the Director of the Liver Institute of Virginia at the Bon Secours Virginia Health System with offices in Richmond and Newport News, Virginia. He is also a Clinical Professor Medicine at the Eastern Virginia Medical School in Norfolk, Virginia. Dr Shiffman received his MD degree from the State University of New York Upstate Medical Center in Syracuse, completed residency and fellowship training in Internal Medicine, Gastroenterology and Hepatology at the Virginia Commonwealth University-Medical College of Virginia. He was the Chief of the Hepatology Section and Medical Director of the Liver Transplant Program at the VCU Medical Center in Richmond, Virginia between 1990-2009. Dr Shiffman has published over 275 articles in peer reviewed medical journals invited reviews and/or book chapters and has edited 3 textbooks on liver disease. He has organized and co-chaired 2 NIH development conferences. He has participated in clinical research studies for many different liver disorders although the majority of his writings and clinical research have focused on viral hepatitis C.

PHC's participations

10th PHC – 2017

Monday, January 30th 2017

Impact of therapy on metabolism and public health

LUNCH WORKSHOPS - 2-How to optimize treatment in G3 patients

9th PHC – 2016

Monday, January 11th 2016

Universal screening? -

Tuesday, January 12th 2016

Lunch Workshops - Room 251 (chairman)

8th PHC – 2015

Monday, January 12th 2015

No -

7th PHC – 2014

Monday, January 13th 2014

Still wait -

6th PHC – 2013

Monday, January 14th 2013

Treat (chairman) -

5th PHC – 2012

Tuesday, January 31st 2012

Telaprevir or Boceprevir ? -

Interactive Luncheons - Room 4 (chairman)

4th PHC – 2011

Monday, January 17th 2011

Is ribavirin still useful?

3rd PHC – 2009

Monday, January 19th 2009

What future for ribavirin ? -

10th PHC – 2017

Monday, January 30th 2017

Impact of therapy on metabolism and public health -

LUNCH WORKSHOPS - 2-How to optimize treatment in G3 patients -